Xeris Biopharma Holdings, Inc. — Form 8-K Summary
Business context and reporting period
Xeris Biopharma Holdings, Inc. filed a Form 8-K dated June 28, 2023, under Item 7.01, Regulation FD Disclosure. The filing reports a change involving the company’s scientific leadership. It does not present quarterly or annual financial results.
Financial and operating metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material changes
- Steven Prestrelski, Ph.D., Founder and Chief Scientific Officer of Xeris Pharmaceuticals, Inc., resigned effective June 30, 2023.
- Beginning July 1, 2023, Dr. Prestrelski entered into a consulting agreement with the company to serve as Senior Scientific Advisor.
- The agreement covers predefined services and continues through January 31, 2025.
Outlook, risks, contingencies, and unusual items
The filing does not disclose compensation terms, termination provisions, financial effects, or specific responsibilities under the consulting agreement. It also provides no updated guidance or outlook. The reported leadership transition may be relevant to investors assessing continuity of scientific strategy and development activities.
Key facts to verify
- Effective date of Dr. Prestrelski’s resignation: June 30, 2023.
- Consulting commencement date: July 1, 2023.
- Consulting end date: January 31, 2025.
- Economic terms and scope of the consulting agreement, which are not disclosed in the filing text.
- Any subsequent filings describing changes to scientific leadership or the consulting arrangement.